Harvard Bioscience, Inc.
HARVARD BIOSCIENCE INC (Form: 4, Received: 09/11/2017 16:05:44)
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

UVEGES GEORGE
2. Issuer Name and Ticker or Trading Symbol

HARVARD BIOSCIENCE INC [ HBIO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

207 WILLOW BROOK DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)

9/7/2017
(Street)

WAYLAND, MA 01778-5124
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   9/7/2017     M    23720   A $2.28   188440   (1) D    
Common Stock   9/7/2017     F    16640   (2) D $3.25   171800   (3) D    
Common Stock   9/7/2017     M    22545   A $2.59   194345   (4) D    
Common Stock   9/7/2017     F    17967   (2) D $3.25   176378   (5) D    
Common Stock   9/7/2017     M    21213   A $2.56   197591   (6) D    
Common Stock   9/7/2017     F    16709   (2) D $3.25   180882   (7) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy)   $2.28   9/7/2017     M         23720   (8)   5/21/2013   5/21/2019   Common Stock, par value $0.01 per share   23720   $0.00   0   D    
Stock option (right to buy)   $2.59   9/7/2017     M         22545   (8)   6/4/2014   6/4/2020   Common Stock, par value $0.01 per share   22545   $0.00   0   D    
Stock option (right to buy)   $2.56   9/7/2017     M         21213   (8)   6/1/2016   6/1/2022   Common Stock, par value $0.01 per share   21213   $0.00   0   D    

Explanation of Responses:
(1)  Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 145,990 shares of common stock held by the Reporting Person.
(2)  Represents the number of shares of common stock that the Reporting Person attested to the ownership thereof in accordance with the Issuer's Third Amended and Restated 2000 Stock Option and Incentive Plan, as amended, in connection with the payment of the option exercise price. With respect to each option exercise, the Issuer only delivered the net amount of the option shares (after reducing the option shares by the amount of shares subject to such attestation) to the Reporting Person and such attestation shares were not sold by the Reporting Person or delivered to the Issuer. Nevertheless, the SEC deems such exercise and related attestation to be a disposition of shares for purposes of Section 16(a) of the Securities Exchange Act of 1934.
(3)  Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 129,350 shares of common stock held by the Reporting Person.
(4)  Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 151,895 shares of common stock held by the Reporting Person.
(5)  Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 133,928 shares of common stock held by the Reporting Person.
(6)  Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 155,141 shares of common stock held by the Reporting Person.
(7)  Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 11,150 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 138,432 shares of common stock held by the Reporting Person.
(8)  Represent the exercise of stock options granted pursuant to the Issuer's 2000 Stock Option and Incentive Plan, as amended.

Remarks:
This form is signed under power of attorney.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
UVEGES GEORGE
207 WILLOW BROOK DRIVE
WAYLAND, MA 01778-5124
X



Signatures
/s/ Chad Porter, by power of attorney 9/11/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.